[IgA nephropathy].
Tomino
Yasuhiko
Y
Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000936:Antigen-Antibody Complex; D015703:Antigens, CD / Q000235:genetics; D037263:Asialoglycoprotein Receptor; D002874:Chromosome Mapping; D018450:Disease Progression; D005922:Glomerulonephritis, IGA / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011961:Receptors, Fc / Q000235:genetics; D012084:Renin-Angiotensin System / Q000235:genetics; D014598:Uteroglobin / Q000235:genetics
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000936:Antigen-Antibody Complex; D015703:Antigens, CD; D037263:Asialoglycoprotein Receptor; C036832:Fc(alpha) receptor; D005938:Glucocorticoids; D007070:Immunoglobulin A; D010975:Platelet Aggregation Inhibitors; D011961:Receptors, Fc; D014598:Uteroglobin